NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $76.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $22.30M, a 696.43% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $54.60M, a 215.61% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $29.60M, a 60.00% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $10.20M, a 1357.14% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $59.90M, a 120.22% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $27.20M, a 1500.00% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.70M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $76.90M 10-Q · filed 2026-08-05 | $106.50M derived: sum of 3 quarters · filed 2026-08-05 | $116.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $54.60M 10-Q · filed 2026-05-07 | $84.20M derived: sum of 2 quarters · filed 2026-05-07 | $94.40M derived: sum of 3 quarters · filed 2026-05-07 | $97.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $29.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $39.80M derived: sum of 2 quarters · filed 2026-02-18 | $42.60M derived: sum of 3 quarters · filed 2026-08-05 | $59.90M 10-K · filed 2026-02-18 |
| 2025-09-30 | $10.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.00M derived: sum of 2 quarters · filed 2026-08-05 | $30.30M 10-Q · filed 2025-11-05 | $48.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $20.10M 10-Q · filed 2026-08-05 | $38.60M derived: sum of 3 quarters · filed 2026-08-05 | $39.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $17.30M 10-Q · filed 2026-05-07 | $35.80M derived: sum of 2 quarters · filed 2026-05-07 | $36.50M derived: sum of 3 quarters · filed 2026-05-07 | $36.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $19.20M derived: sum of 2 quarters · filed 2026-02-18 | $19.20M derived: sum of 3 quarters · filed 2026-02-18 | $27.20M 10-K · filed 2026-02-18 |
| 2024-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $700.00K derived: sum of 2 quarters · filed 2025-11-05 | $8.70M 10-Q · filed 2025-11-05 | $8.70M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.00M 10-Q · filed 2025-08-06 | $8.00M derived: sum of 3 quarters · filed 2026-02-18 | $9.60M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $8.00M 10-Q · filed 2025-05-08 | $8.00M derived: sum of 2 quarters · filed 2026-02-18 | $9.60M derived: sum of 3 quarters · filed 2026-02-18 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.60M derived: sum of 2 quarters · filed 2026-02-18 | $1.70M 10-K · filed 2026-02-18 | |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.70M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |